B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.

Bcl-xL, which is highly expressed in MCC, appears to be an attractive therapeutic target for the treatment of this tumor; especially since the effect of specific Bcl-xL inhibitors is synergistically enhanced by simultaneous PARP inhibition.